by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles GLP-1 receptor agonists, including semaglutide and tirzepatide, significantly reduce cardiometabolic risk factors such as dyslipidemia, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, obstructive sleep apnea, chronic...
by MM360 Staff | May 31, 2025 | Uncategorized
Source: ASCO Daily News Dr. John Sweetenham shares highlights from Day 2 of the 2025 ASCO Annual Meeting, including new data on the treatment of ER+/HER2-negative breast cancer and potentially practice-changing results for patients with cutaneous squamous cell...
by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles At the 2025 National Lipid Association (NLA) Scientific Sessions, Marlys L. Koschinsky, PhD, FNLA, discusses the role of Lp(a) in cardiovascular risk and the emerging therapies designed to target and lower Lp(a) levels. Read...
by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles Gurjyot K. Doshi, MD, discusses key updates to medically integrated pharmacy standards, which reflect the evolving landscape of oral oncolytic therapy. Read More
